Overview

• Drug concept: Develop a small molecule for cancer immunotherapy that targets immunosuppressive cell trafficking to increase ICT
  response rate
• Target class: EVT801 is a selective inhibitor of the VEGFR3 tyrosine kinase
• Project status: EVT801 is currently in late preclinical development and is anticipated to be Phase 1 ready in Q3 2018
• Targeted indication: Combination with immune checkpoint therapies for non-responder patients with VEGFR3+ microenvironment
• Gateway indication: Solid tumours with VEGFR3+ microenvironment and/or Kaposi’s sarcoma as orphan disease
• Administration: Oral administration
• Biomarkers: Patient stratification: VEGFR3 expression on TME & circulating MDSCs quantification
  PD biomarker: ERK/AKT phosphorylation & gene signature
  Biomarker of activity: Gene signature & circulating immune-cells quantification

_{1 Evotec, Toulouse, France}

_{2 Sanofi, Marcy l’étoile, France}

_{3 CHU de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France}

_{4 Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France}

_{5 Donogh O’Brien BioConsulting, Les Poirioux, France}

_{6 present affiliation: Onxeo, Paris, France}